Shares of DexCom Inc. (NASDAQ:DXCM) have earned an average rating of “Buy” from the seventeen ratings firms that are currently covering the company. Three investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $92.31.
DXCM has been the topic of several recent analyst reports. B. Riley initiated coverage on shares of DexCom in a report on Monday, September 26th. They issued a “neutral” rating and a $97.00 target price on the stock. Zacks Investment Research lowered shares of DexCom from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 4th. BTIG Research raised shares of DexCom from a “neutral” rating to a “buy” rating and set a $92.00 target price on the stock in a report on Monday, October 31st. Wedbush reissued an “outperform” rating and issued a $112.00 target price (up from $100.00) on shares of DexCom in a report on Wednesday, November 2nd. Finally, Canaccord Genuity decreased their target price on shares of DexCom from $100.00 to $70.00 and set a “buy” rating on the stock in a report on Wednesday, November 2nd.
In related news, EVP Richard Doubleday sold 3,182 shares of DexCom stock in a transaction that occurred on Friday, December 23rd. The shares were sold at an average price of $62.17, for a total transaction of $197,824.94. Following the sale, the executive vice president now directly owns 83,582 shares in the company, valued at approximately $5,196,292.94. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider John Lister sold 15,000 shares of DexCom stock in a transaction that occurred on Friday, January 13th. The stock was sold at an average price of $79.36, for a total transaction of $1,190,400.00. Following the sale, the insider now owns 85,598 shares in the company, valued at $6,793,057.28. The disclosure for this sale can be found here. Corporate insiders own 2.80% of the company’s stock.
A number of large investors have recently bought and sold shares of the company. BNP Paribas Arbitrage SA raised its position in DexCom by 3,320.0% in the third quarter. BNP Paribas Arbitrage SA now owns 1,197 shares of the medical device company’s stock valued at $105,000 after buying an additional 1,162 shares during the last quarter. Bellwether Investment Group LLC purchased a new position in DexCom during the second quarter valued at about $119,000. Global X Management Co. LLC raised its position in DexCom by 118.9% in the third quarter. Global X Management Co. LLC now owns 1,900 shares of the medical device company’s stock valued at $167,000 after buying an additional 1,032 shares during the last quarter. Capstone Asset Management Co. purchased a new position in DexCom during the third quarter valued at about $205,000. Finally, Profund Advisors LLC purchased a new position in DexCom during the third quarter valued at about $205,000.
Shares of DexCom (NASDAQ:DXCM) opened at 84.16 on Thursday. DexCom has a 1-year low of $47.92 and a 1-year high of $96.38. The company’s 50 day moving average is $65.50 and its 200-day moving average is $79.15. The company’s market capitalization is $7.11 billion.
DexCom Company Profile
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products include SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile.